These results indicate a new molecular basis for the clinical and experimental finding that high Mn in the brain is a risk factor to develop AD pathology and cognitive impairments, that is, Mn can increase both APP gene expression and amyloidogenic APP processing that produces Aβ 1–42. The gene discussed is APP; the disease is Cognitive impairment.